WO2004087181A2 - Combinaisons de principes actifs d'huiles contenant des acides gras $g(v)3 avec des extraits vegetaux contenant des polyphenols et utilisation desdites combinaisons - Google Patents

Combinaisons de principes actifs d'huiles contenant des acides gras $g(v)3 avec des extraits vegetaux contenant des polyphenols et utilisation desdites combinaisons Download PDF

Info

Publication number
WO2004087181A2
WO2004087181A2 PCT/EP2004/003401 EP2004003401W WO2004087181A2 WO 2004087181 A2 WO2004087181 A2 WO 2004087181A2 EP 2004003401 W EP2004003401 W EP 2004003401W WO 2004087181 A2 WO2004087181 A2 WO 2004087181A2
Authority
WO
WIPO (PCT)
Prior art keywords
diseases
active ingredient
oil
treatment
ingredient combination
Prior art date
Application number
PCT/EP2004/003401
Other languages
German (de)
English (en)
Other versions
WO2004087181A3 (fr
WO2004087181A8 (fr
Inventor
Egon Koch
Karl-Heinz Stumpf
Original Assignee
Bioplanta Arzneimittel Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioplanta Arzneimittel Gmbh filed Critical Bioplanta Arzneimittel Gmbh
Priority to BRPI0409139-6A priority Critical patent/BRPI0409139A/pt
Priority to MXPA05010416A priority patent/MXPA05010416A/es
Priority to CA002521040A priority patent/CA2521040A1/fr
Priority to EP04724578A priority patent/EP1608387A2/fr
Publication of WO2004087181A2 publication Critical patent/WO2004087181A2/fr
Publication of WO2004087181A8 publication Critical patent/WO2004087181A8/fr
Publication of WO2004087181A3 publication Critical patent/WO2004087181A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/38—Clusiaceae, Hypericaceae or Guttiferae (Hypericum or Mangosteen family), e.g. common St. Johnswort
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/45—Ericaceae or Vacciniaceae (Heath or Blueberry family), e.g. blueberry, cranberry or bilberry
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/535—Perilla (beefsteak plant)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/55—Linaceae (Flax family), e.g. Linum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A61K36/734—Crataegus (hawthorn)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/77—Sapindaceae (Soapberry family), e.g. lychee or soapberry
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/80—Scrophulariaceae (Figwort family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Definitions

  • the present invention relates to active ingredient combinations of ⁇ 3-fatty acid-containing oils with polyphenolic-containing plant extracts and their use for the treatment of inflammatory and / or immunological and metabolic diseases and other disorders.
  • ⁇ 3 fatty acids are responsible for the • disease process in chronic inflammatory and / or immunological diseases, such as ⁇ .
  • B. favorably affect atherosclerosis, coronary heart disease, rheumatoid arthritis, psoriasis etc. It is also reported that these fatty acids have preventive and protective effects in fat metabolism disorders or diabetes and are therefore suitable for the treatment of vascular and neurological disorders, such as those that occur in these diseases.
  • ⁇ 3 fatty acids With a lack of ⁇ 3 fatty acids in the diet, visual and central nervous disorders as well as hemorrhagic dermatitis, growth disorders and delayed wound healing were observed. Since the mammal organism is unable to synthesize these compounds itself, it is dependent on food.
  • ⁇ 3 fatty acids prevent the formation of pro-inflammatory prostaglandins and leukotrienes from arachidonic acid by displacing this fatty acid from its binding in the SN2 position of phospholipids in the cell membranes.
  • Polyunsaturated fatty acids such as B. ⁇ -linolenic acid, eicosapentaenoic acid or docosahexaenoic acid are extremely sensitive to oxidation. The incorporation such fatty acids or their secondary products in cellular membranes therefore increases the organism's need for antioxidants.
  • polyphenols includes simple phenol carboxylic acids such as. As gentisic acid, protocatechic acid, gallic acid or caffeic acid, flavones such as. As camphor oil, quercetin, myricetin, isorhamnetin, naringenin, 6-prenylnaringenin, 8-prenylnaringenin, isoxanthohumol and their glycosides, chalcones such as. B. xanthohumol, isoflavones such as. B.
  • anthocyanins such as. As pelargonidine, cyanidine, malvidin or delphinidine, tanning agents such as. B. catechin and epicatechin, their oligomers and polymers and lignans. All of these compounds are reducing agents and, along with other antioxidant substances, e.g. As vitamins C and E, to protect the body against oxidative stress. Oxidative stress is a condition in the body in which the formation of oxidants and free radicals exceeds the body's ability to inactivate these substances. As a result, proteins, DNA and lipids as well as cell membranes and other structural elements are damaged.
  • oxidation products are involved in the development of common diseases such as atherosclerosis, chronic inflammation, cancer or diabetes and accelerate the aging process.
  • the amount of free radicals depends on lifestyle (diet, smoking, exercise) and is influenced by existing illnesses (eg hypercholesterolemia, diabetes).
  • a particularly rich source of oxygen radicals are e.g. B. neutrophilic granulocytes, which release these compounds in inflammatory reactions. Since endogenously formed molecules or enzymes with an antioxidative effect cannot be influenced in their concentration or activity by exogenous measures, the intake of antioxidants via nutrition is of crucial importance.
  • the object of the present invention is to provide means for the prevention and treatment of inflammatory and immunological diseases and of tumor disorders.
  • This object is achieved by a combination of active ingredients comprising at least one oil containing ⁇ 3 fatty acid and at least one plant extract containing polyphenol, which at the same time compensates for a deficiency in ⁇ 3 fatty acids and antioxidative polyphenols, prevents such a deficiency or an increased need for these substances in the case of inflammatory and / or immunological and metabolic diseases and tumor disorders.
  • this combination of active substances counteracts two important factors involved in the pathogenesis of inflammatory reactions and metabolic diseases. It also has the advantage that the oxidation-sensitive ⁇ 3 fatty acids are protected from degradation by the antioxidative action of the polyphenols and / or vitamins both during storage and after incorporation in cell membranes.
  • a preferred ⁇ 3 fatty acid is ⁇ -linolenic acid, which is contained, for example, about 50-60% in the oil from the seeds of Perilla frutescens (Perillaöll). For this reason, perilla oil is a preferred ⁇ 3 fatty acid oil.
  • suitable oils include borage oil, evening primrose seed oil, fish oil, currant seed oil and linseed oil.
  • Preferred polyphenol-containing plant extracts are extracts from Aspalathus linearis, Crataegus species, Ginkgo biloba, Humulus lupulus, Hypericum perforatum, Paullinia cupana, Rubus fructicosus, Rubus idaeus, Tabebuia avellanedae, The obroma cacao, Vaccinium myrtilla and Vitis vinifer.
  • the polyphenol-containing plant extract preferably contains at least 15% by weight of polyphenols, based on the dry extract.
  • Active substance combinations which contain one of the following combinations are preferred: extract from Vitis vinifera and perilla seed oil, extract from Vaccinium myrtillus and linseed oil, extract from ginkgo biloba and linseed oil, extract from crataegus and borage oil, extract from Aspalathus linearis and borage oil, extract from Theobroma cacao and evening primrose seed oil, extract from Tabebuia avellanedae and evening primrose seed oil, extract from fish oil, extract from Hypericumupulus and undatum Fish oil, extract from Paullinia cupana and currant kernel oil, extract from Rubus idaeus and currant kernel oil, extract from Rubus fructicosus and perilla seed oil, extract from Aspalathus linearis and perilla seed oil as well as extract from Humulus lupulus and perilla seed oil.
  • the extracts can be prepared in a variable composition with solvents such as e.g. B. water, methanol, ethanol, 2-propanol, acetone, etc. and mixtures thereof at temperatures from room temperatures to 100 ° C with gentle to vigorous mixing or by percolation within 10 minutes to 24 hours under normal pressure or elevated pressure be preserved.
  • solvents such as e.g. B. water, methanol, ethanol, 2-propanol, acetone, etc. and mixtures thereof at temperatures from room temperatures to 100 ° C with gentle to vigorous mixing or by percolation within 10 minutes to 24 hours under normal pressure or elevated pressure be preserved.
  • further concentration steps can be carried out, e.g. B. liquid-liquid distribution with z. B. 1-butanol water or ethyl acetate / water, adsorption-desorption on ion exchanger, LH20, HP20 and other resins or chromatographic separations over RP18, silica gel, etc.
  • the further processing to dry extracts is
  • the active substance combinations according to the invention can be used for the treatment, for the support of the treatment or for the prophylaxis of inflammatory and / or immunological and metabolic diseases and other disorders, such as, for. B. rheumatoid arthritis, polyarthritis, synovitis, acne, neurodermatitis, psoriasis, asthma, hay fever, atherosclerosis, coronary heart disease or arrhythmia, of chronic bowel diseases, such as. B. ulcerative colitis or Crohn's disease, as well as polyneuropathies, retinopathies, cerebral and peripheral arterial circulatory disorders, psychiatric disorders such as. B. depression, schizophrenia, bipolar disorder, and tumor diseases.
  • rheumatoid arthritis polyarthritis, synovitis, acne, neurodermatitis, psoriasis, asthma, hay fever, atherosclerosis, coronary heart disease or arrhythmia
  • chronic bowel diseases such as. B. ulcerative colitis or Crohn's disease,
  • the active ingredient combination according to the invention can be in the form of a dietetic food or pharmaceutical.
  • the active substance combinations according to the invention are preferably administered as part of a balanced diet.
  • the drug combinations can additional components such.
  • B. Vitamin C and / or E are added to compensate for their deficiency or to ensure their increased need.
  • the active substance combinations according to the invention are well suited for filling into capsules.
  • other substances such as B. partially or fully hydrogenated vegetable oils, beeswax, lecithin, neutral oil, hard fat and highly disperse silicon dioxide can be added to the capsule filling compound in order to adjust the consistency of the mixtures and to prevent segregation of the liquid component and solid plant extract.
  • amphiphilic, surface-active substances and emulsifiers such as. B. Sorbitan monooleate can be added.
  • the plant extract is mixed with the oil (both according to the table below) and the flowable suspension obtained is filled into capsules using a suitable method.
  • ⁇ 3-fatty acid-containing oils and polyphenol-containing plant extracts described in the preceding examples are distinguished by the fact that they inhibit the synthesis of pro-inflammatory eicosanoids and the neutralization of free radicals. They also have the advantage that the oxidation-sensitive ⁇ 3 fatty acids are protected from degradation by the antioxidative effect of the polyphenols both during storage and after incorporation in cell membranes.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des combinaisons de principes actifs d'huiles contenant des acides gras φ3 avec des extraits végétaux contenant des polyphénols et l'utilisation desdites combinaisons dans le traitement de maladies inflammatoires et/ou immunologiques et méboliques ainsi que d'autres affections.
PCT/EP2004/003401 2003-04-02 2004-03-31 Combinaisons de principes actifs d'huiles contenant des acides gras $g(v)3 avec des extraits vegetaux contenant des polyphenols et utilisation desdites combinaisons WO2004087181A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
BRPI0409139-6A BRPI0409139A (pt) 2003-04-02 2004-03-31 combinação de ingredientes ativos de óleos que contêm ácido graxo w3 com extratos de plantas que contêm polifenol e uso destes
MXPA05010416A MXPA05010416A (es) 2003-04-02 2004-03-31 Combinacion de substancias activas de aceites minerales que contienen acidos grasos (3 con extractos vegetales que contengan polifenoles y su uso.
CA002521040A CA2521040A1 (fr) 2003-04-02 2004-03-31 Combinaisons de principes actifs d'huiles vegetales contenant des acides gras .omega.3 avec de extraits vegetaux contenant des polyphenols et utilisation connexe
EP04724578A EP1608387A2 (fr) 2003-04-02 2004-03-31 COMBINAISONS DE PRINCIPES ACTIFS D'HUILES CONTENANT DES ACIDES GRAS w3 AVEC DES EXTRAITS VEGETAUX CONTENANT DES POLYPHENOLS ET UTILISATION DESDITES COMBINAISONS

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10315025.0 2003-04-02
DE10315025A DE10315025A1 (de) 2003-04-02 2003-04-02 Wirkstoffkombination von ω3-fettsäurehaltigen Ölen mit polyphenolhaltigen Pflanzenextrakten und deren Verwendung

Publications (3)

Publication Number Publication Date
WO2004087181A2 true WO2004087181A2 (fr) 2004-10-14
WO2004087181A8 WO2004087181A8 (fr) 2004-12-29
WO2004087181A3 WO2004087181A3 (fr) 2005-04-21

Family

ID=32980960

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/003401 WO2004087181A2 (fr) 2003-04-02 2004-03-31 Combinaisons de principes actifs d'huiles contenant des acides gras $g(v)3 avec des extraits vegetaux contenant des polyphenols et utilisation desdites combinaisons

Country Status (7)

Country Link
EP (1) EP1608387A2 (fr)
BR (1) BRPI0409139A (fr)
CA (1) CA2521040A1 (fr)
DE (1) DE10315025A1 (fr)
MX (1) MXPA05010416A (fr)
RU (1) RU2005130342A (fr)
WO (1) WO2004087181A2 (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1618875A1 (fr) * 2003-04-08 2006-01-25 Kirin Beer Kabushiki Kaisha Composition destinee a l'inhibition ou a la prevention de la baisse de la densite osseuse et boisson correspondante
WO2006120360A2 (fr) * 2005-05-13 2006-11-16 Persee Medica Composition pour traiter ou prevenir les troubles liés à un dérèglement de l'horloge biologique
EP2135616A1 (fr) * 2008-06-19 2009-12-23 Symrise GmbH & Co. KG Fruit d'airelle séché destiné à influencer l'état de l'intestin
WO2010000564A2 (fr) * 2008-06-09 2010-01-07 Nestec S.A. Rooibos et inflammation
US8597692B2 (en) 2007-04-26 2013-12-03 Barry Callebaut Ag Cocoa extract and use thereof
US8603547B2 (en) 2007-04-26 2013-12-10 Barry Callebaut Ag Use of cocoa extract
US8709503B2 (en) 2007-04-26 2014-04-29 Barry Callebaut Ag Use of cocoa extract

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8257751B2 (en) * 2003-11-03 2012-09-04 Beauté Pacifique ApS Composition for the cosmetic treatment of age-related dermatological symptoms
DE102005035864A1 (de) * 2005-07-30 2007-02-01 Beiersdorf Ag Verwendung von Xanthohumol und/oder Isoxanthohumol zur Herstellung von kosmetischen oder dermatologischen Zubereitungen zur Behandlung und/oder Prophylaxe der Symptome der intrinsischen und/oder extrinsischen Hautalterung sowie zur Behandlung und Prophylaxe der schädlichen Auswirkungen ultravioletter Strahlung auf die Haut
DE102006033321A1 (de) * 2006-07-17 2008-01-24 Westfälische Wilhelms-Universität Münster Medizinische Verwendung von N-Phenylpropenoyl-Aminosäurederivaten und verwandten Verbindungen
FR2912918A1 (fr) * 2007-02-27 2008-08-29 Persee Medica Soc Par Actions Utilisation d'acides gras polyinsatures et de flavonoides en tant qu'agents actifs dans une composition pour la prevention et/ou le traitement des cephalees.
WO2015154192A1 (fr) * 2014-04-11 2015-10-15 George Robertson Utilisation d'une composition contenant un flavonol, un flavonoïde et un acide gras dans le traitement de lésions oxydatives causées par un dysfonctionnement mitochondrial
CN109316535A (zh) * 2017-07-31 2019-02-12 格特生物制药（天津）有限公司 一种治疗鸡滑膜炎的中药组合物及其制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2770974A1 (fr) * 1997-11-20 1999-05-21 Hatem Smaoui Nouveau complement nutritionnel a base de lycopene de tomate, d'acides gras r 3-6-9 et antioxydants primaires et secondaires
WO2004087114A1 (fr) * 2003-04-02 2004-10-14 Bioplanta Arzneimittel Gmbh Capsules pour administration orale a action retardee du contenu de la capsule
WO2004087180A1 (fr) * 2003-04-02 2004-10-14 Bioplanta Arzneimittel Gmbh Compositions qui comprennent des huiles contenant des acides gras omega-3 et des extraits vegetaux

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0558901A (ja) * 1991-08-26 1993-03-09 Teikoku Hormone Mfg Co Ltd 骨吸収抑制因子およびその製造方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2770974A1 (fr) * 1997-11-20 1999-05-21 Hatem Smaoui Nouveau complement nutritionnel a base de lycopene de tomate, d'acides gras r 3-6-9 et antioxydants primaires et secondaires
WO2004087114A1 (fr) * 2003-04-02 2004-10-14 Bioplanta Arzneimittel Gmbh Capsules pour administration orale a action retardee du contenu de la capsule
WO2004087180A1 (fr) * 2003-04-02 2004-10-14 Bioplanta Arzneimittel Gmbh Compositions qui comprennent des huiles contenant des acides gras omega-3 et des extraits vegetaux

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
CZYGAN F-C: "Redbush-tea - Aspalathus linearis" ZEITSCHRIFT FUR PHYTOTHERAPIE 2002 GERMANY, Bd. 23, Nr. 6, 2002, Seiten 295-298, XP009033111 ISSN: 0722-348X *
DATABASE BIOSIS [Online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; Dezember 1999 (1999-12), KANG HAN-CHUL ET AL: "Extraction and mixing effects of grape (Campbell) seed oil" XP002308812 Database accession no. PREV200000129154 & AGRICULTURAL CHEMISTRY AND BIOTECHNOLOGY, Bd. 42, Nr. 4, Dezember 1999 (1999-12), Seiten 175-179, ISSN: 0368-2897 *
DATABASE BIOSIS [Online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; Juni 1998 (1998-06), LEE BONG-HO ET AL: "References review of the scientific researches on perilla" XP002308811 Database accession no. PREV199800504419 & RDA JOURNAL OF INDUSTRIAL CROP SCIENCE, Bd. 40, Nr. 1, Juni 1998 (1998-06), Seiten 80-112, ISSN: 1226-5624 *
FREMONT LUCIE ET AL: "Antioxidant activity of resveratrol and alcohol-free wine polyphenols related to LDL oxidation and polyunsaturated fatty acids" LIFE SCIENCES, Bd. 64, Nr. 26, 21. Mai 1999 (1999-05-21), Seiten 2511-2521, XP002308810 ISSN: 0024-3205 *
GRIMM H ET AL: "Regulatory potential of n-3 fatty acids in immunological and inflammatory processes" BRITISH JOURNAL OF NUTRITION, Bd. 87, Nr. Supplement 1, Januar 2002 (2002-01), Seiten S59-S67, XP009033127 ISSN: 0007-1145 *
GRIMMINGER F ET AL: "Use of n-3 fatty acid-containing lipid emulsions in the intensive care unit environment: The clinician's view" CLINICAL NUTRITION 2002 UNITED KINGDOM, Bd. 21, Nr. SUPPL. 2, 2002, Seiten 23-29, XP009033130 ISSN: 0261-5614 *
JOUBERT E ET AL: "Antioxidants of rooibos tea - a possible explanation for its health promoting properties?" SOUTH AFRICAN JOURNAL OF FOOD SCIENCE AND NUTRITION 1996 INFRUITEC, PRIVATE BAG X5013, STELLENBOSCH 7599, SOUTH AFRICA, Bd. 8, Nr. 3, 1996, Seite 79, XP009033126 *
NARISAWA T ET AL: "COLON CANCER PRECENTION WITH A SMALL AMOUNT OF DIETARY PERILLA IOL HIGH IN ALPHA-LNOLENIC ACID IN AN ANIMAL MODEL" CANCER, AMERICAN CANCER SOCIETY, PHILADELPHIA, PA, US, Bd. 73, Nr. 8, 15. April 1994 (1994-04-15), Seiten 2069-2075, XP001037789 ISSN: 0008-543X *
PATENT ABSTRACTS OF JAPAN Bd. 0173, Nr. 67 (C-1082), 12. Juli 1993 (1993-07-12) & JP 05 058901 A (TEIKOKU HORMONE MFG CO LTD), 9. März 1993 (1993-03-09) *
SCHULZ H: "Red bush in cosmetics" COSSMA 2000 GERMANY, Bd. 1, Nr. 4, 2000, Seiten 22-23, XP009033110 ISSN: 1439-7676 *
See also references of EP1608387A2 *
YOSHINO KYOJI ET AL: "Antioxidative and hypolipidemic effects of dietary green tea polyphenols in ddY mice fed fish oil-rich diet" JOURNAL OF THE FOOD HYGIENIC SOCIETY OF JAPAN, Bd. 39, Nr. 3, Juni 1998 (1998-06), Seiten 192-198, XP009033072 ISSN: 0015-6426 *

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1618875A1 (fr) * 2003-04-08 2006-01-25 Kirin Beer Kabushiki Kaisha Composition destinee a l'inhibition ou a la prevention de la baisse de la densite osseuse et boisson correspondante
EP1618875A4 (fr) * 2003-04-08 2006-05-24 Kirin Brewery Composition destinee a l'inhibition ou a la prevention de la baisse de la densite osseuse et boisson correspondante
WO2006120360A2 (fr) * 2005-05-13 2006-11-16 Persee Medica Composition pour traiter ou prevenir les troubles liés à un dérèglement de l'horloge biologique
WO2006120360A3 (fr) * 2005-05-13 2007-11-08 Persee Medica Composition pour traiter ou prevenir les troubles liés à un dérèglement de l'horloge biologique
US8597692B2 (en) 2007-04-26 2013-12-03 Barry Callebaut Ag Cocoa extract and use thereof
US8603547B2 (en) 2007-04-26 2013-12-10 Barry Callebaut Ag Use of cocoa extract
US8709503B2 (en) 2007-04-26 2014-04-29 Barry Callebaut Ag Use of cocoa extract
WO2010000564A2 (fr) * 2008-06-09 2010-01-07 Nestec S.A. Rooibos et inflammation
EP2133088A3 (fr) * 2008-06-09 2010-01-27 Nestec S.A. Rooibos et inflammation
WO2010000564A3 (fr) * 2008-06-09 2010-02-25 Nestec S.A. Rooibos et inflammation
EP2135616A1 (fr) * 2008-06-19 2009-12-23 Symrise GmbH & Co. KG Fruit d'airelle séché destiné à influencer l'état de l'intestin
EP2135616B1 (fr) 2008-06-19 2016-05-04 Symrise AG Fruit d'airelle séché destiné à influencer l'état de l'intestin

Also Published As

Publication number Publication date
WO2004087181A3 (fr) 2005-04-21
DE10315025A1 (de) 2004-10-14
BRPI0409139A (pt) 2006-03-28
EP1608387A2 (fr) 2005-12-28
RU2005130342A (ru) 2006-03-27
MXPA05010416A (es) 2006-03-21
WO2004087181A8 (fr) 2004-12-29
CA2521040A1 (fr) 2004-10-14

Similar Documents

Publication Publication Date Title
DE60122196T2 (de) Synergistische antioxidans-kombination von delta tocols und polyphenolen
AT407821B (de) Mittel auf der basis von naturstoffen
JP2018505866A (ja) マルチサプリメント組成物
EP1377273B1 (fr) Procede de production d'un concentre d'isoflavone
DE60027481T2 (de) Zusammensetzung zur Behandlung von chronischer venöser Insuffizienz mit einem Extrakt aus Blättern von roten Weinreben
WO2004087181A2 (fr) Combinaisons de principes actifs d'huiles contenant des acides gras $g(v)3 avec des extraits vegetaux contenant des polyphenols et utilisation desdites combinaisons
EP3651805A2 (fr) Solubilisat contenant de la curcumine et optionnellement au moins une autre substance active
US9034399B2 (en) Dietary compositions for promoting brain health
EP1091659B1 (fr) Forme galenique orale
EP1305013A1 (fr) Preparation antioxydante protegeant contre les affections vasculaires et son utilisation
EP2282751B1 (fr) Combinaison d'extraits de plantes possédant une spécificité de compartiment et contenant un extrait de ginkgo biloba et de ginseng exerçant un effet tandem
DE10315026A1 (de) Zusammensetzungen enthaltend omega-3-fettsäurehaltige Öle und Pflanzenextrakte
EP1608345A1 (fr) Capsules pour administration orale a action retardee du contenu de la capsule
EP2485718A1 (fr) Utilisation d'une composition à base d' érémophilanolides
JP2000072685A (ja) 消化器潰瘍を抑制するための食品および医薬組成物
JP2009196967A (ja) 血中多価不飽和脂肪酸相対量増加剤並びにこれを含有する医薬組成物、医薬部外品、化粧品、可食性組成物及び動物用飼料
EP1541037A1 (fr) Composition orale contenant un extrait de Passiflora incarnata
DE102011052708A1 (de) Verfahren zum Schutz photolabiler Wirkstoffe
LU500687B1 (de) Nahrungs- oder diätische zusammensetzung
WO2022162597A1 (fr) Combinaisons d'extraits de scutellaria avec des extraits de citrus bergamia ou de cynara cardunculus et formulations les contenant
WO2009071564A1 (fr) Composition pharmaceutique pour le traitement du paludisme
DE202023103890U1 (de) Extrakt aus Amlafrüchten und selbigen beinhaltende Nährstoffzusammensetzung
EP4255490A1 (fr) Matrice eutectique pour compositions nutraceutiques
KR20030073995A (ko) 항염, 항자극 효과가 있는 복령 추출물을 함유하는 화장료조성물과 그의 제조방법
IT202000029747A1 (it) Composizione ad attivita’ protettiva su cellule neuronali per prevenire e trattare un disturbo neurocognitivo

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 42/2004 UNDER (81) REPLACE "DE" BY "DE (UTILITY MODEL)"

WWE Wipo information: entry into national phase

Ref document number: 2004724578

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: PA/a/2005/010416

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2521040

Country of ref document: CA

Ref document number: 2005130342

Country of ref document: RU

WWP Wipo information: published in national office

Ref document number: 2004724578

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0409139

Country of ref document: BR

DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)